Clinical Trial Results:
            A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies 
    
|     Summary | |
|     EudraCT number | 2004-001483-51 | 
|     Trial protocol | FI GB SE IT DK AT ES | 
|     Global completion date | 
                                    20 Sep 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v2(current) | 
|     This version publication date | 
                                    21 Oct 2021
                             | 
|     First version publication date | 
                                    15 Feb 2017
                             | 
|     Other versions | v1 | 
|     Version creation reason | 
 | 
|     Summary report(s) | CAMN107A2101.CTR.19Aug2016 Full results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
